ReviewTherapeutics and clinical risk management2015

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis.

Philipp Diehl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.